Update on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF?

Update: 2025-01-07

Description

With Nikolaus Marx, Chair of Task Force of the 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes, RWTH University Hospital Aachen, Aachen - Germany and Ruxandra Christodorescu, University of Medicine and Pharmacy Victor Babes, Timisoara - Romania.

In this podcast, Nikolaus Marx joins Ruxandra Christodorescu to discuss updates on heart failure and diabetes: what is the potential role of semaglutide and the combination of GIP-GLP1 receptor agonists in the management of HF?

Comments

In Channel

Sleep apnoea in people with ortolayrngeal problems

2025-09-0811:36

What cardiologists should know about sleep apnoea

2025-09-0812:12

Dyspnoea of unknown cause

2025-08-0814:38

Stroke prevention in heart failure

2025-06-3014:38

Atrial fibrillation screening in patients with cryptogenic stroke

2025-06-0311:42

Patent foramen ovale

2025-06-0316:35

Cardiovascular risk factors in older adults

2025-05-0217:36

Stroke in older adults

2025-05-0215:19

Hypertension and heart failure

2025-04-0311:29

Hypertension in pregnancy

2025-04-0320:36

To be or not to be invasive in CCS patients: how to choose

2025-03-0312:45

Anatomic vs functional tests in CCS patients: how to choose

2025-03-0313:12